Gasdermin-D activation by SARS-CoV-2 triggers NET and mediate COVID-19 immunopathology.
Camila Meirelles S SilvaCarlos Wagner S WanderleyFlavio Protasio VerasAugusto Velozo GonçalvesMikhael Haruo Fernandes LimaJuliana Escher Toller-KawahisaGiovanni Freitas GomesDaniele Carvalho NascimentoValter V Silva MonteiroIsadora Marques PaivaCícero José Luíz Ramos AlmeidaDiego Brito CaetitéJuliana Costa SilvaMaria Isabel Fernandes LopesLetícia Pastorelli BonjornoMarcela Cavichioli GianniniNatalia Brasil AmaralMaíra Nilson BenattiRodrigo Carvalho SantanaLuis Eduardo Alves DamascenoBruna Manuella Souza SilvaAyda Henriques SchneiderIcaro Maia Santos CastroJuan Carlo Santos SilvaAmanda Pereira VasconcelosTiago Tomazini GonçalvesSabrina Setembre BatahTamara Silva RodriguesVictor Ferreira CostaMarjorie Cornejo PontelliRonaldo B MartinsTimna Varela MartinsDanillo Lucas Alves EspósitoGuilherme Cesar Martelossi CebinelliBenedito Antônio Lopes da FonsecaLuiz Osório Silveira LeiriaLarissa Dias CunhaEurico ArrudaHelder I NakaiaAlexandre Todorovic FabroRene D R OliveiraDario S ZamboniPaulo Louzada-JuniorThiago Mattar CunhaJosé Carlos Farias Alves-FilhoFernando de Queiroz CunhaPublished in: Critical care (London, England) (2022)
These results demonstrated that GSDMD-dependent NETosis plays a critical role in COVID-19 immunopathology and suggests GSDMD as a novel potential target for improving the COVID-19 therapeutic strategy.